StockData
Damora Therapeutics, Inc. logo

Damora Therapeutics, Inc. (DMRA) stock

DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$22.98+0.42 (+1.86%)

Close on Nov 18, 2026Market cap $1.42BP/E 5.8Yield 0.00%

Damora Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

No revenue figures for Damora Therapeutics

Damora Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Damora Therapeutics figures

See a number that looks wrong?